Medline ® Abstract for Reference 150
of 'Chemotherapy for advanced exocrine pancreatic cancer'
Domchek SM, Hendifar AE, McWilliams RR, et al. RUCAPANC: An open-label, phase 2 trial of the PARP inhibitor rucaparib in patients (pts) with pancreatic cancer (PC) and a known deleterious germline or somatic BRCA mutation (abstract). J Clin Oncol 34,2016 (suppl; abstr 4110). http://meetinglibrary.asco.org/content/166810-176 (Accessed on June 24, 2016).
no abstract available